NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn. , Sept. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective September 20, 2022, the Compensation Committee of the Board of Directors approved two equity awards under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "Inducement Plan"), as a material inducement to the individuals entering into employment with the Company.

NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q3 2022 Earnings Conference Call August 11, 2022 5:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Third Quarter of Fiscal Year 2022 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) CEO Dave Rosa on Q3 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn. , Aug. 11, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter of fiscal year 2022 ended June 30, 2022.

NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Company re-submits application to gain FDA clearance for less than 30 day use EDEN PRAIRIE, Minn. , Aug. 9, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company submitted a special 510(k) to the U.S. Food and Drug Administration ("FDA") on August 8 th for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.

NeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode

EDEN PRAIRIE, Minn. , Aug. 4, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter of fiscal 2022 ended June 30, 2022, on August 11, 2022 at 5:30 PM Eastern Time.

NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11

Amendment provides Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share EDEN PRAIRIE, Minn. , Aug. 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc. ("Zimmer") that will provide the Company with a $3.5 million accelerated payment within 10 business days which relates to certain milestone payments.

NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode

Case performed at Emory University for intraoperative brain mapping EDEN PRAIRIE, Minn. , July 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo sEEG electrode was performed by Dr. Robert Gross at Emory University.

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode

Letter recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond EDEN PRAIRIE, Minn. , June 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's Proxy Statement for its Annual Meeting of Stockholders that occurred on May 31, 2022.

NeuroOne® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders

EDEN PRAIRIE, Minn. , May 19, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:  NMTC ) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will present at the H.C.

NeuroOne® to Present Its Breakthrough Technology for Monitoring Neural Activity at the H.C. Wainwright Global Investment Conference on May 25

The Evo®  sEEG electrode 510(k) cleared for temporary (less than 24 hours) use remains in effect and the Company will explore the opportunity to market the device for intraoperative use. EDEN PRAIRIE, Minn.

NeuroOne Provides Evo® sEEG Update

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Dave Rosa – Chief Executive Officer Ron Mcclurg – Chief Financial Officer Conference Call Participants Connor Stevenson – Craig-Hallum Ben Haynor – Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the NeuroOne Medical Technologies Corporation Second Quarter of Fiscal 2022 Earnings Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and its Chief Financial Officer, Ron Mcclurg.

NeuroOne Medical Technologies' (NMTC) CEO Dave Rosa on Q2 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn. , May 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022.

NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn. , May 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its second quarter of fiscal 2022, ended March 31, 2021, on May 12, 2022 at 4:30 PM Eastern Time.

NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12

EDEN PRAIRIE, Minn. , April 18, 2022  /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022.

NeuroOne® to Present its Disruptive Next-Generation Diagnostic Electrode Technology at the NobleCon18 Investor Conference on April 20, 2022

EDEN PRAIRIE, Minn. , March 30, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that a telephone replay of its investor conference call discussing recent disclosures, held yesterday, will be available through April 11, 2022.

NeuroOne® Investor Call Replay Available Through April 11th

EDEN PRAIRIE, Minn. , March 28, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will host a conference call to discuss recent disclosures tomorrow, March 29, 2022, at 10:00 am Eastern Time.

NeuroOne® to Host Investor Call About Recent Disclosures Tomorrow March 29th at 10:00 am ET

EDEN PRAIRIE, Minn., March 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it is scheduled to attend two investor conferences during the month of March 2022.

NeuroOne to Present its Game-Changing Neuroscientific Technology at the Oppenheimer 32nd Annual Healthcare Conference and 34th Annual ROTH Conference

EDEN PRAIRIE, Minn., March 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial bench top, long-term stimulation testing on a novel design of its thin film electrode technology.

NeuroOne® Releases Successful Completion of Long-Term Stimulation Tests for its Novel Thin Film Platform Electrode Technology

NeuroOne Medical Technologies Corporation (NMTC) CEO Dave Rosa on Q1 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Feb. 14, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces its operating results for the first quarter of fiscal year 2022 ended December 31, 2021.

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Feb. 8, 2022  /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology.

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology

EDEN PRAIRIE, Minn., Feb. 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its first quarter of fiscal 2022, ended December 31, 2021, on February 14, 2022 at 4:30 PM Eastern Time.

NeuroOne to Host First Quarter Fiscal Year 2022 Earnings Call

EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs.

NeuroOne Appoints Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs

EDEN PRAIRIE, Minn., Dec. 20, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, was featured on The Medical Alley Podcast, in an episode titled "A Conversation with Dave Rosa, President and CEO, NeuroOne.

NeuroOne Featured on The Medical Alley Podcast: "A Conversation with Dave Rosa, President and CEO, NeuroOne"

NeuroOne Medical Technologies' (NMTC) CEO Dave Rosa on Q4 2021 Earnings Call Transcript

News for NeuroOne Medical Technologies Corp Stock (NMTC)